| 股號 / 名稱 | 現金及約當現金 | 流動資產 | 總資產 |
| TMO 賽默飛世爾科技 | 180,071,345,100.43 | 844,630,563,037.45 | 3,766,725,867,946.79 |
| ABT 美國雅培 | 133,610,893,672.76 | 774,758,528,562.48 | 3,569,343,141,015.61 |
| LH Labcorp Holdings Inc. | 8,632,609,072.93 | 130,781,719,270.71 | 624,020,907,798.5 |
| DGX 奎斯特診斷 | 26,280,326,322.11 | 102,780,146,983.71 | 567,846,298,109.23 |
| A 安捷倫 | 57,968,398,587.54 | 154,747,266,536.59 | 460,548,704,819.21 |
| BIO Bio-Rad Laboratories, Inc. | 15,342,830,411.14 | 101,513,943,055.52 | 355,562,593,179.35 |
| ILMN Illumina Inc | 42,503,564,152.07 | 100,076,274,012.05 | 224,619,301,011.56 |
| QGEN QIAGEN N.V. | 25,340,565,594.16 | 54,625,719,139.3 | 194,190,903,810.32 |
| NTRA Natera, Inc. | 36,178,974,452.93 | 56,801,512,529.97 | 90,626,402,846.4 |
| TEM Tempus AI, Inc. | 19,470,490,346.74 | 37,487,451,126.85 | 80,839,141,092.39 |
| GH Guardant Health, Inc. | 33,859,348,209.79 | 44,297,517,920.65 | 62,177,273,634.47 |
| VCYT Veracyte, Inc. | 6,589,140,587.57 | 15,427,837,539.44 | 51,876,638,730.51 |
| NEO NeoGenomics, Inc. | 4,592,660,138.61 | 13,522,101,705.33 | 45,402,544,640.48 |
| BLLN BillionToOne, Inc. | 18,515,330,732.47 | 22,491,375,937.3 | 25,076,443,368.51 |
| CSTL Castle Biosciences, Inc. | 2,571,778,884.78 | 11,767,024,354.24 | 19,105,434,521.51 |
| 4169 泰宗 | 1,082,514,000 | 1,546,656,000 | 2,061,220,000 |
| 6598 ABC-KY | 405,713,000 | 928,864,000 | 1,056,189,000 |
載入數據中...
和癌症診斷相關的產業概念股
癌症診斷概念股相關指標排名
癌症診斷每月營收
癌症診斷每股盈餘
癌症診斷每股淨值
癌症診斷損益表
癌症診斷總資產
癌症診斷負債和股東權益
癌症診斷現金流量表
癌症診斷利潤比率
癌症診斷營業費用率拆解
癌症診斷杜邦分析
癌症診斷ROE / ROA
癌症診斷經營週轉能力
癌症診斷營運週轉天數
癌症診斷現金股利發放率
癌症診斷財務結構比率
癌症診斷流速動比率
癌症診斷利息保障倍數
癌症診斷現金流量分析
癌症診斷營業現金流對淨利比
癌症診斷盈餘再投資比率
癌症診斷月營收成長率
癌症診斷營收成長率
癌症診斷毛利成長率
癌症診斷營業利益成長率
癌症診斷稅後淨利成長率
癌症診斷每股盈餘成長率
癌症診斷本益比評價
癌症診斷股價淨值比評價
癌症診斷現金股利殖利率
癌症診斷平均現金股息殖利率
癌症診斷董監持股比例
癌症診斷董監持股質押比例